A Phase III Long-Term Extension Trial with Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants with Major Depressive Disorder (EXTEND)

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jan 2025 According to a Cybin Inc. media release, EXTEND is expected to begin 12 weeks after commencement of APPROACH and EMBRACE.
13 Jan 2025 According to a Cybin Inc. media release, initiation of the study expected in the first quarter of 2025.
03 Dec 2024 According to a Cybin Inc. media release, the initiation of the Phase III PARADIGM program, its design, enrollment process, and milestone targets will be discussed during in the Water Tower Research Fireside Chat Series taking place on Wednesday, December 11, 2024, at 11:00 a.m. ET.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com